Clinical Studies (BA/BE/In-vitro)
Nestled in the evolving state of Goa, VerGo Pharma (Clinicals Division) is a world-class Clinical Research Organization (CRO) built to meet global regulatory standards. With advanced infrastructure and scientific expertise, we deliver end-to-end solutions encompassing BA/BE studies, in-vitro research and diverse clinical services, supporting pharmaceutical and healthcare clients across highly regulated global markets.
Our Capabilities, Accreditations & Expertise in Clinical Studies:
- Facility audited and approved by: CDSCO India, USFDA, UK MHRA, NPRA Malaysia, WHO-Geneva, CMPC Kazakhstan
- 166-bed facility spread across 4 clinical units
- Diversified database of 22,000+ volunteers
- Conducted 850+ BA/BE Studies, across regulated markets
- BA/BE studies on healthy volunteers & special populations – Solid Oral (Tablets/Capsules), Suspensions, Liquids, Suppositories, Oral Thin Films, Injectables
- Comprehensive BA/BE solutions from protocol development to final eCTD dossier submission
- Full-service Clinical Data Management and Regulatory Affairs support for bio-equivalence studies for global submissions
- Robust Bio-analytical Capabilities: 260+ Validated Methods; 50+ Methods under development (including simultaneous estimations)
- GLP-compliant Bio-analytical Lab equipped with 10 LCMS-MS
- Pathology Lab: ISO 15189:2022 Certified; NABL Accredited
- Independent in-vitro testing laboratory
Types of Studies
- BA/BE
- Fasting Studies
- Fed Studies
- Steady State (Multiple Dose Studies)
- Pharmacokinetic Studies
- In-Vitro Studies >> Click here to know more
- IVRT Studies
- IVPT Studies
- In-vitro Enteral Feeding Tube Studies
- BCS Studies
- In-vitro Binding Studies
Dosage Forms Supported
- Solid Oral (Tablets, Capsules)
- Oral Suspensions & Liquids
- Oral Thin Films
- Suppositories
- Injectables
Regulatory Track Record
VerGo Pharma has a proven history of successful inspections and approvals from leading global
authorities, including:
- CDSCO (India)
- USFDA
- MHRA (UK)
- NPRA (Malaysia)
- WHO-Geneva
- CMPC (Kazakhstan)
Strategic Advantage
VerGo Pharma delivers a unique edge by combining clinical expertise, quality compliance and global regulatory accreditation with the integrated strength of a CDMO + CRO model – all co-located in Goa.
- Accelerated Development Timelines: Seamless transition from formulation and analytical development to clinical studies shortens pathways to approval.
- Regulatory Confidence: Proven track record with global ensures smooth submissions and approvals.
- Facility audited and approved by: CDSCO India, USFDA, UK MHRA, NPRA Malaysia, WHO-Geneva, CMPC Kazakhstan.
- Our successful submissions to regulatory agencies includes EU, US, UK, Canada, ASEAN, LatAm, Australia & Emerging Markets.
- Competitive Positioning: Quality-driven research and dossier readiness, enhance brand
reputation and market success. - Integrated CDMO + CRO Advantage: One-partner solution for end-to-end drug development,
from formulation scale-up to bioequivalence studies and dossier out-licensing or
commercialisation. - Location Advantage: With both CDMO and CRO units being located in Goa, VerGo Pharma
ensures operational efficiency, cost-effective scalability and seamless product development and
commercialization.